BACE

Signaling Pathway Map

Research Area

Inhibitory Selectivity

BACE Products

New BACE Products
Catalog No. Information Product Use Citations Product Validations
S2156

LY2886721

LY2886721 is a BACE inhibitor used for the treatment of Alzheimer's Disease. Phase 1/2.

S1528

LY2811376

LY2811376 is the first orally available non-peptidic β-secretase(BACE1) inhibitor with IC50 of 239 nM-249 nM, that act to decrease Aβ secretion with EC50 of 300 nM, demonstrated to have 10-fold selectivity towards BACE1 over BACE2, and more than 50-fold inhibition over other aspartic proteases including cathepsin D, pepsin, or renin. Phase 1.

S6503New

LX2343

LX2343 is a multi-target agent that exhibits a high capability for ameliorating multi-abnormalities of AD pathogenesis. It is a BACE1 enzyme inhibitor with an IC50 value of 11.43±0.36 μM.

S8564

Verubecestat (MK-8931)

Verubecestat (MK-8931) is a potent and selective beta-secretase (also known as Beta-site APP-cleaving enzyme 1) inhibitor.

S8193

Lanabecestat(AZD3293, LY3314814)

Lanabecestat(AZD3293, LY3314814)is an oral beta-secretase 1 cleaving enzyme (BACE) inhibitor with an inhibitory constant Ki of 0.4 nM.

S8600New

Elenbecestat

Elenbecestat is a novel BACE1 inhibitor, demonstrating prolonged reductions in plasma beta-amyloid levels after single dosing.

S3835

Loganin

Loganin is an iridoid glycoside first isolated from the seeds of Strychnos nux-vomica, a member of the Loganiaceae family. It is a non-competitive inhibitor of BACE1 with IC50 of 47.97 μM an also inhibits AChE and BChE with IC50 values of 3.95 μM and 33.02 μM, respectively.

S8173

Verubecestat (MK-8931) Trifluoroacetat

Verubecestat (MK-8931) is a potent and selective beta-secretase inhibitor and BACE1 protein inhibitor or Beta-site APP-cleaving enzyme 1 inhibitor.

S7731

AZD3839

AZD3839 is a potent and selective BACE1 inhibitor with Ki of 26.1 nM, about 14-fold selectivity over BACE2. Phase 1.

Catalog No. Information Product Use Citations Product Validations
S2156

LY2886721

LY2886721 is a BACE inhibitor used for the treatment of Alzheimer's Disease. Phase 1/2.

S1528

LY2811376

LY2811376 is the first orally available non-peptidic β-secretase(BACE1) inhibitor with IC50 of 239 nM-249 nM, that act to decrease Aβ secretion with EC50 of 300 nM, demonstrated to have 10-fold selectivity towards BACE1 over BACE2, and more than 50-fold inhibition over other aspartic proteases including cathepsin D, pepsin, or renin. Phase 1.

S6503New

LX2343

LX2343 is a multi-target agent that exhibits a high capability for ameliorating multi-abnormalities of AD pathogenesis. It is a BACE1 enzyme inhibitor with an IC50 value of 11.43±0.36 μM.

S8564

Verubecestat (MK-8931)

Verubecestat (MK-8931) is a potent and selective beta-secretase (also known as Beta-site APP-cleaving enzyme 1) inhibitor.

S8193

Lanabecestat(AZD3293, LY3314814)

Lanabecestat(AZD3293, LY3314814)is an oral beta-secretase 1 cleaving enzyme (BACE) inhibitor with an inhibitory constant Ki of 0.4 nM.

S8600New

Elenbecestat

Elenbecestat is a novel BACE1 inhibitor, demonstrating prolonged reductions in plasma beta-amyloid levels after single dosing.

S3835

Loganin

Loganin is an iridoid glycoside first isolated from the seeds of Strychnos nux-vomica, a member of the Loganiaceae family. It is a non-competitive inhibitor of BACE1 with IC50 of 47.97 μM an also inhibits AChE and BChE with IC50 values of 3.95 μM and 33.02 μM, respectively.

S8173

Verubecestat (MK-8931) Trifluoroacetat

Verubecestat (MK-8931) is a potent and selective beta-secretase inhibitor and BACE1 protein inhibitor or Beta-site APP-cleaving enzyme 1 inhibitor.

S7731

AZD3839

AZD3839 is a potent and selective BACE1 inhibitor with Ki of 26.1 nM, about 14-fold selectivity over BACE2. Phase 1.